Drugs

Conclusions of FDA-EMA Parallel Assessment of Quality-By-Design Elements of Marketing Applications

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are publishing a series of joint question-and-answer documents that outline the conclusions of their first parallel assessment of quality-by-design (QbD) elements of a marketing authorization application.

One of the projected outcomes of this pilot was to share key findings with the public. FDA and EMA will publish additional question-and-answer documents on other QbD-related topics as the pilot program continues and more parallel assessments are conducted.

In March 2011, FDA and EMA launched a pilot program, in which both agencies communicated review findings about QbD elements of applications chosen for the pilot.

QbD is a science- and risk-based approach to pharmaceutical development and manufacturing. QbD in pharmaceuticals involves designing and developing pharmaceutical formulations and manufacturing processes to help ensure product quality. 

As part of this pilot program, U.S. and European regulators communicate and consult throughout the review process relevant QbD aspects of the new drug and supplement applications. This parallel assessment aids sharing of regulatory decisions and facilitates the availability of consistent quality pharmaceutical products throughout the United States and the European Union.

Both agencies found the parallel assessment useful and reached agreement on a wide range of QbD aspects. At the request of the applicant, experts from the Japanese Pharmaceuticals Medical Devices Agency also participated as observers in this first parallel assessment.
 

Page Last Updated: 12/19/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.